体重指数并非唯一标准，专家介绍，国内体重指数标准但拥有腹型肥胖的患者不在少数。男性腰围≥90cm，女性腰围≥85cm则为腹型肥胖，腹型肥胖的 病人，由于内脏上附着了大量脂肪，所以负担较重。 央视网消息：10月8日是第28个全国高血压日，宣传主题是"健康体重，理想血压"。数据显示，我国30岁至79岁成年人中约29%患有高血压，防控形势 严峻。我们先来了解一下，体重与高血压有哪些关联？都有哪些因素会引发高血压？ 肥胖易导致高血压 需警惕腹型肥 什么是标准体重？可以来算一算你的体重指数，计算公式为：体重（kg）÷ 身高的平方（m2）。 根据世界卫生组织标准，体重指数18.5以下为偏瘦， 18.5-24.9为正常，25-29.9为超重，30及以上为肥胖。数据显示，体重指数每增加5，高血压的发病风险就会增加49%。 专家指出，睡眠也与高血压密切相关。晚睡晚起和睡眠质量差，容易导致负责应激反应的交感神经长时间处于兴奋状态。 高血压治疗要及时 生活习惯调控是关键 高血压是导致心脑血管疾病的核心危险因素，长期血压升高会直接损伤血管壁、增加心脏负荷，引发动脉硬化、心肌梗死、脑卒中等疾病。 那么，高血压应如何防治？生活中哪些习惯 ...

Summary of Mineralys Therapeutics Conference Call Company Overview - **Company**: Mineralys Therapeutics (NasdaqGS:MLYS) - **Product**: Lorundrostat, an aldosterone synthase inhibitor targeting hypertension, particularly in patients with hyperaldosteronism-driven, uncontrolled, and resistant hypertension Key Points and Arguments 1. **Clinical Success**: Mineralys has achieved successful clinical outcomes in its pivotal program for lorundrostat, with an upcoming FDA filing and preparations for commercial launch expected soon [1][3] 2. **Target Population**: Approximately 30% of hypertension patients exhibit elevated or dysregulated aldosterone, confirming the need for aldosterone-targeted treatments [4] 3. **Market Approach**: The initial market strategy is to target fourth-line treatment for resistant hypertension, with plans to expand into third-line treatment over time [6][9] 4. **Guideline Inclusion**: The company is working closely with key opinion leaders to include lorundrostat in treatment guidelines, which is expected to be achievable based on rigorous trial data [7][8] 5. **Patient Population**: There are about 10 million potential patients with resistant hypertension in the U.S., with an additional 10 million in the third-line category [9][10] 6. **Safety and Efficacy Data**: The company does not anticipate additional incidences of hyperkalemia over time and plans to share comprehensive data with the FDA during the NDA submission [10][11] 7. **Competitive Landscape**: Recent phase three data on Baqsrostat showed comparable results to lorundrostat, but lorundrostat's profile is viewed favorably due to its efficacy and specificity [12][13] 8. **Partnership Opportunities**: Mineralys is open to partnerships to maximize the commercial potential of lorundrostat, especially given the focused nature of the prescribing physician base [18][19] 9. **Independent Launch Considerations**: While an independent launch is feasible, the company believes partnering would enhance market access and efficiency [20][21] 10. **Additional Indications**: Ongoing trials for chronic kidney disease (CKD) and obstructive sleep apnea (OSA) are aimed at establishing a broader treatment profile for lorundrostat [22][24] 11. **Future Development**: Heart failure is identified as a potential area for future research with aldosterone synthase inhibitors [25] 12. **Impact of Weight Loss Treatments**: The rise of GLP-1s and other weight loss treatments may affect the hypertension market, but there remains a significant opportunity for lorundrostat due to the prevalence of elevated aldosterone [26] Additional Important Insights - The company is focused on ensuring that lorundrostat is recognized as a viable treatment option for patients with comorbidities such as CKD and OSA [22][24] - The competitive landscape is evolving, and the company is prepared to address potential counter-detailing from competitors regarding treatment profiles [17] - The overall market for hypertension treatments remains robust, with a significant number of patients requiring effective management strategies [26]

Summary of Alnylam Pharmaceuticals (ALNY) Update / Briefing - August 30, 2025 Company Overview - **Company**: Alnylam Pharmaceuticals (ALNY) - **Key Product**: Zalbesiran, a novel treatment for uncontrolled hypertension - **Collaboration**: Partnership with Roche for the development of Zalbesiran Industry Context - **Focus Area**: Cardiovascular disease, specifically hypertension - **Global Burden**: Cardiovascular disease is the leading cause of death worldwide, with approximately 20 million deaths annually attributed to it, primarily due to high blood pressure [11][12] - **Treatment Gap**: Less than 40% of women and 30% of men achieve adequate blood pressure control, highlighting a significant unmet need in hypertension management [13] Core Points and Arguments Clinical Development and Results - **CARDIA Trials**: The presentation focused on the results of the CARDIA three trial, which evaluated Zalbesiran in patients with uncontrolled hypertension and high cardiovascular risk [27][38] - **Efficacy**: - CARDIA one showed a significant reduction in blood pressure of 15 mmHg as monotherapy [28] - CARDIA two demonstrated reductions of -19 mmHg with a diuretic, -10 mmHg with amlodipine, and -7 mmHg with olmesartan [29] - CARDIA three results indicated a placebo-adjusted reduction of -5 mmHg and -3.3 mmHg for the 300 mg and 600 mg doses, respectively, at three months [34][38] - **Safety Profile**: The safety profile was encouraging, with low rates of serious adverse events and manageable instances of hyperkalemia and kidney dysfunction [36] Mechanism of Action - **RNA Interference Technology**: Zalbesiran utilizes RNA interference to silence genes associated with hypertension, allowing for infrequent dosing (once every six months) [4][5] - **Blood Pressure Control**: The drug aims to provide consistent blood pressure control, addressing both daytime and nighttime variability, which is crucial for reducing cardiovascular risk [17][21] Market Opportunity - **Patient Population**: There are approximately 219 million patients with hypertension in major markets, with 62 million currently uncontrolled [40] - **Unmet Need**: Patients with uncontrolled hypertension and high cardiovascular risk represent a significant unmet need, particularly those with comorbidities like diabetes and chronic kidney disease [40] Future Directions - **Phase Three Trial (Zenith)**: The upcoming Zenith trial will enroll 11,000 patients with uncontrolled hypertension and established cardiovascular disease, focusing on cardiovascular outcomes [43][45] - **Regulatory Engagement**: The protocol for the Zenith trial has been filed with multiple regulators, with plans to activate sites soon [45] - **Commercial Strategy**: Alnylam and Roche are developing strategies for the commercialization of Zalbesiran, including potential additional indications [46][47] Important but Overlooked Content - **Adherence Issues**: The challenge of treatment adherence in chronic diseases like hypertension is significant, with about 40% of patients not taking their medications as prescribed [22][23] - **Long Duration of Action**: The six-month duration of action for Zalbesiran is highlighted as a major advantage in improving adherence and overall treatment outcomes [24][51] - **Synergistic Effects with Diuretics**: The potential for Zalbesiran to work synergistically with diuretics is noted, as diuretics can upregulate the renin-angiotensin system, enhancing the effectiveness of Zalbesiran [60][63] Conclusion - **Transformational Potential**: Zalbesiran is positioned as a potentially paradigm-shifting therapy for hypertension, with the ability to improve blood pressure control and cardiovascular outcomes significantly [55][56]

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a peak increase of over 15% and a closing rise of more than 50% recently, indicating strong market interest and potential investor confidence in the company [1]. Group 1: Market Reaction - Baixinan-B's stock price rose by 11.4% to HKD 10.36, with a trading volume of HKD 42.644 million [1]. Group 2: Industry Developments - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. - Renal denervation (RDN) has been added as a recommended treatment option in the updated guidelines [1]. Group 3: Regulatory Changes - The Centers for Medicare & Medicaid Services (CMS) proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period [1]. - The final decision on the new RDN insurance proposal is expected to be announced by October 8, 2025, or earlier [1].

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a rise of over 50% recently, driven by updates in hypertension management guidelines and potential insurance coverage for renal denervation (RDN) procedures [1]. Group 1: Stock Performance - Baixinan-B's stock rose over 15% at one point and closed up more than 50% yesterday, currently trading at 10.36 HKD with a trading volume of 42.644 million HKD [1]. Group 2: Industry Guidelines - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. Group 3: Insurance Coverage Proposal - The Centers for Medicare & Medicaid Services (CMS) proposed new insurance coverage for RDN, suggesting it be included for patients with uncontrolled hypertension [1]. - The proposal has entered a 30-day public comment period, with a final decision expected to be announced by October 8, 2025 [1].

Core Viewpoint - The release of the 2025 ACC/AHA hypertension clinical guidelines indicates a new direction for hypertension prevention and treatment, highlighting the need for innovative solutions like renal denervation (RDN) to address the global challenge of uncontrolled hypertension [1]. Group 1: Differences Between US and China Guidelines - The US guidelines emphasize early intervention and precise stratification, setting the hypertension threshold at 130/80 mmHg to promote proactive management [2]. - The control targets in the US guidelines recommend a universal goal of <130/80 mmHg, with further specifications for high cardiovascular risk patients to lower systolic pressure to <130 mmHg, ideally <120 mmHg [3]. - In contrast, the Chinese guidelines set the hypertension threshold at 140/90 mmHg, aligning with local epidemiological characteristics and focusing on practical clinical management [4][5]. Group 2: RDN Clinical Application Under Guidelines - The 2025 US hypertension guidelines outline a comprehensive process for RDN application, emphasizing "precise selection, collaborative decision-making, and long-term management" [6]. - RDN is primarily indicated for patients with resistant hypertension, specifically those requiring three or more antihypertensive medications without achieving control [7]. - A multidisciplinary team (MDT) is essential for evaluating patients for RDN, ensuring thorough screening for secondary hypertension and contraindications [9]. Group 3: RDN as a New Treatment Option - RDN is recognized as a valuable adjunct treatment for resistant hypertension, with a recommendation level of 2b, B-R in the 2025 guidelines, indicating its use under specific conditions [11]. - The Iberis RDN system demonstrates significant efficacy, with a study showing a 13 mmHg reduction in 24-hour ambulatory systolic blood pressure and a 21 mmHg reduction in office systolic blood pressure at six months post-treatment [13]. - RDN offers a continuous blood pressure-lowering effect, providing a promising solution for patients with difficult-to-treat hypertension [13][14].

Core Viewpoint - The American Heart Association and the American College of Cardiology have released a new hypertension clinical practice guideline, marking the first update since 2017, which emphasizes early intervention and treatment for borderline hypertension [1][2]. Summary by Relevant Sections Hypertension Guidelines - The new guideline maintains the target blood pressure values for adults: normal blood pressure is below 120/80 mmHg, and elevated blood pressure ranges from 120-129/80 mmHg. Action is required if blood pressure is 130/80 mmHg or higher [1]. - For systolic blood pressure between 130 and 139 mmHg, lifestyle changes should be the first step. If blood pressure does not reach the target range after 3 to 6 months, medication is recommended, differing from the previous guideline which suggested medication for systolic pressure above 140 mmHg [1]. Lifestyle Adjustments - Recommended lifestyle adjustments include maintaining a healthy weight, following a heart-healthy diet, reducing sodium intake, managing stress, engaging in moderate physical activity, and limiting or abstaining from alcohol [1][2]. - The new guideline advises minimizing alcohol consumption, with the ideal choice being complete abstinence, contrasting with the previous recommendation of limited daily alcohol intake [2]. Dietary Recommendations - The dietary recommendations remain consistent, emphasizing increased consumption of fruits, vegetables, whole grains, and low-fat dairy while reducing saturated fat and total fat intake. Sodium intake should be less than 2,300 mg per day, with an ideal target of 1,500 mg [2]. - For overweight or obese individuals, a weight loss of at least 5% is recommended, with clinically proven interventions suggested for those with severe obesity [2]. Publication - The new guidelines have been published in the Journal of the American College of Cardiology [3].

Misconceptions about Hypertension Treatment - Misconception 1: No symptoms means no medication is needed. Early-stage hypertension often shows no symptoms, but untreated high blood pressure can severely damage organs like the heart, brain, and kidneys, necessitating active intervention once diagnosed [1] - Misconception 2: Normal blood pressure allows for stopping medication. Hypertension is a chronic condition requiring long-term medication to control blood pressure, as stopping can lead to rebound hypertension and increased risk of complications like myocardial infarction and stroke [3] - Misconception 3: Antihypertensive drugs are addictive. Antihypertensive medications are non-addictive, and while they may be temporarily stopped in cases of stress-induced hypertension, diagnosed patients must adhere to their medication regimen to prevent blood pressure from rising again [4] - Misconception 4: Initial treatment should not use "good drugs." Long-acting antihypertensive medications are preferred for stable blood pressure control, while short-acting drugs are reserved for acute situations [6] - Misconception 5: High blood pressure should be rapidly normalized. Blood pressure should be lowered gradually to avoid complications like cerebral hypoperfusion, with a focus on a slow, steady, and moderate reduction [7] - Misconception 6: Single blood pressure measurement is sufficient for diagnosis. A proper diagnosis of hypertension requires multiple measurements over different days, as occasional high readings can be due to anxiety [9] - Misconception 7: Frequent changes in medication are beneficial. Finding the right antihypertensive medication can take time, and once stable, patients should continue with their regimen unless adverse effects occur [10] - Misconception 8: Self-medicating based on others' experiences is safe. Hypertension has various causes and individual responses to treatment can differ, making it essential to follow a doctor's guidance for medication [12] - Misconception 9: Health supplements can effectively lower blood pressure. Many believe in the efficacy of health supplements for blood pressure control, but these claims lack scientific validation and can delay proper treatment [13] - Misconception 10: Intravenous treatment is necessary for hypertension. Most cases of hypertension should be managed with oral medications, reserving intravenous treatment for acute hypertensive crises [14] - Misconception 11: Lower blood pressure is always better. Extremely low blood pressure can compromise organ perfusion, leading to serious conditions like cerebral thrombosis [16] - Misconception 12: Regular check-ups are unnecessary. Patients should have periodic evaluations to monitor for adverse drug reactions and assess the impact on target organs, even if blood pressure appears stable [17]

Core Insights - The innovative drug Rulitan® (generic name: Aliskiren Indapamide Sustained-release Tablets) has been launched on JD Health, marking a significant advancement in hypertension treatment in China [1][2] - Rulitan® is the first ARNI + thiazide-like diuretic fixed-dose combination antihypertensive drug developed exclusively by the company, utilizing a triple mechanism for blood pressure reduction [1] - The prevalence of hypertension among adults in China is approximately 27.5%, highlighting a substantial market opportunity for effective treatment options [1] Company Strategy - The company plans to strategically cover various segments of hypertension patients with Rulitan®, complementing its existing products such as Xintan® (Aliskiren Tablets), Xinchao® (Sacubitril Aliskiren Calcium Tablets), and Rulitan® (Aliskiren Amlodipine Tablets) [2] - The collaboration with JD Health aims to enhance the accessibility of innovative drugs, addressing clinical needs and benefiting a larger patient population [2] Market Context - Hypertension is a systemic disease that can lead to severe complications such as stroke, coronary heart disease, heart failure, and renal failure, emphasizing the importance of effective treatment options [1] - The drug is particularly suitable for patients with salt-sensitive hypertension, elderly patients, and those with comorbidities such as diabetes and metabolic syndrome [1]

Core Viewpoint - The article highlights the significant advancements in hypertension treatment with the successful clinical application of the Iberis RDN system at Hospital Universitario de Torrejón de Ardoz in Madrid, emphasizing its academic value and clinical potential in treating uncontrolled hypertension [2][5]. Group 1: Technological Innovation - The Iberis RDN system represents a breakthrough in renal denervation (RDN) procedures by utilizing the radial artery for access, which reduces trauma and recovery time compared to traditional femoral artery approaches [5]. - The system employs a unique design with a circular four-electrode ablation mechanism and a <4Fr catheter, allowing for precise adaptation to the complex anatomy of renal arteries, enhancing treatment efficacy [10]. - Integrated features such as wall contact testing, precise temperature control, and safety cut-off functions improve the accuracy and stability of the procedure [10]. Group 2: Clinical Outcomes - A case study reported a 43-year-old patient with hereditary resistant hypertension who experienced significant symptom improvement and reduced medication usage following the RDN procedure, showcasing the system's effectiveness [7]. - The rapid recovery and positive feedback from patients have been noted as redefining the recovery experience for hypertension surgeries [7]. Group 3: Future Prospects - The Iberis RDN technology is expected to benefit Spanish hypertension patients, particularly those with poor drug control or intolerance to multiple medications, providing new treatment pathways [8]. - The recognition of the technology's safety and efficacy by Spanish media supports its potential for broader application, including improvements in arrhythmia management [8]. - Ongoing multi-center clinical practices and evidence development are anticipated to further validate the technology's potential in diverse applications for hypertension treatment [8].